

Bulletin Number: MSA 06-68

Distribution: Community Mental Health Services Program Clinics
County Health Plans
Federally Qualified Health Centers
Outpatient Hospitals
Practitioners (DO & MD)
Rural Health Clinics
Tribal Health Centers

Issued: October 1, 2006

Subject: Change in Reimbursement of Psychotropic Injectable Drugs for ABW Beneficiaries

Effective: November 1, 2006

Programs Affected: Adult Benefits Waiver

The purpose of this policy is to explain a change in the payment responsibility for certain psychotropic injectable drugs for Adult Benefits Waiver (ABW) beneficiaries enrolled in county health plans (CHPs).

Effective for dates of service on or after November 1, 2006, a physician who administers specific psychotropic injectable drugs through a Community Mental Health Services Program (CMHSP) clinic to an ABW beneficiary enrolled in a CHP may bill Michigan Department of Community (MDCH) if all of the following criteria are met:

- The beneficiary has an open case with the CMHSP
- The beneficiary receives the injections on a scheduled or routine basis as part of the CMHSP treatment/supports regimen
- The CMHSP physician has determined that the beneficiary may not comply with the medication regimen if the injections were not administered through CMHSP clinic and that this noncompliance could adversely affect the beneficiary
- The CMHSP clinic notifies the beneficiary's CHP or primary care physician that this service is being rendered

The injectable drugs included in this change are:

- Haloperidol (e.g., Haldol)
- Haloperidol Decanoate (e.g., Haldol-D)
- Fluphenazine Decanoate (e.g., Prolixin)
- Benzotropine Mesylate (e.g., Cogentin)
- Lorazepam (e.g. Ativan)
- Diphenhydramine HCl
- Adrenalin, Epinephrine
- Risperidone, Long Acting (e.g., Risperdal Consta)
- Olanzapine (e.g., Zyprexa)
- Ziprasidone Mesylate (e.g., Geodon)

Note: This list of injectable drugs may be modified as new drugs are approved for Adult Benefits Waiver coverage. The “MDCH PIHP/CMHSP Physician Injectable Drug Coverage for Beneficiaries Enrolled in Medicaid Health Plans” list of current approved drugs for ABW beneficiaries will be maintained on the MDCH website at www.michigan.gov/mdch. Providers are encouraged to monitor the website for changes.

Injectable drugs that do not meet the above criteria remain the responsibility of the CHP and the CHP’s prior authorization requirements must be followed.

The specific Injectable drugs are only covered by MDCH through the Fee-For-Service Program if provided by a physician as part of his affiliation with a CMHSP, and must be billed using the Medicaid ID number associated with the CMHSP. Payments made to a physician for injectable drugs administered to ABW beneficiaries that are billed under a physician’s Medicaid ID number not associated with a CMHSP physician group will be subject to recovery.

Manual Maintenance

Retain this bulletin until the information has been incorporated into the Michigan Medicaid Provider Manual.

Questions

Any questions regarding this bulletin should be directed to Provider Inquiry, Department of Community Health, P.O. Box 30731, Lansing, Michigan 48909-8231, or e-mail at ProviderSupport@michigan.gov. When you submit an e-mail, be sure to include your name, affiliation, and phone number so you may be contacted if necessary. Providers may phone toll-free 1-800-292-2550.

Approved



Paul Reinhart, Director
Medical Services Administration